Prednisolone Phosphoric Acid

Summary

Prednisolone Phosphoric Acid (CHEMBL1201231) is an approved small-molecule anti-inflammatory agent; indicated across 1 condition including herpes simplex virus keratitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 440.4 Da · C21H29O8P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201231
Name	Prednisolone Phosphoric Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	72078
ChEBI	CHEBI:145705
Molecular formula	C21H29O8P
Molecular weight	440.4
InChIKey	JDOZJEUDSLGTLU-VWUMJDOOSA-N

SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)(O)O)O)CCC4=CC(=O)C=C[C@]34C)O

IUPAC name: [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] dihydrogen phosphate

ChEBI definition: A synthetic glucocorticoid resulting from the formal condensation of the 21-hydroxy group of prednisolone with one of the hydroxy groups of phosphoric acid. It is a prodrug for prednisolone that is activated in vivo by phosphatases.

Pharmacological roles (ChEBI): anti-inflammatory agent, glucocorticoid receptor agonist, prodrug, antineoplastic agent.

Also known as: Prednisolone phosphoric acid, Prednisolone phosphate, prednisolone phosphate, PREDNISOLONE PHOSPHORIC ACID

Parent form; salt/anhydrous children: CHEMBL1201014

Patent coverage: 375 distinct patent families (1,571 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
herpes simplex virus keratitis	3	MONDO:0015288	EFO:0007308

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000138	PHASE3	UNKNOWN	Herpetic Eye Disease Study (HEDS) I

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).